Showing 3491-3500 of 5646 results for "".
- Alcon Announces US Launch of Tryptyr for Dry Eye Diseasehttps://modernod.com/news/alcon-announces-us-launch-of-tryptyr-for-dry-eye-disease/2482908/Alcon announced the US commercial availability of Tryptyr (acoltremon ophthalmic solution) 0.003% for the treatment of the signs and symptoms of dry eye disease (DED). Approved by the FDA in May, eye care professionals (ECPs) across the US can officially begin p
- Ziemer USA Announces New Innovations for the Galilei Diagnostic Platform and FEMTO LDV Z8 Femtosecond Laserhttps://modernod.com/news/ziemer-usa-announces-new-innovations-for-the-galilei-diagnostic-platform-and-femto-ldv-z8-femtosecond-laser-platform/2482904/Ziemer USA, in partnership with CorneaGen, announced the launch of the Galilei CTAK module, which is now available for use with the Galilei diagnostic platform. "We are thrilled to complete our product offering for CTAK patients. With the addition of the Galilei CTAK module in combination
- Alcon Showcases Surgical Efficiency of Unity VCS Innovations at ASRS 2025https://modernod.com/news/alcon-showcases-surgical-efficiency-of-unity-vcs-innovations-at-asrs-2025/2482903/Alcon will showcase its latest clinical data and innovations at the 2025 American Society of Retina Specialists (ASRS) annual meeting, July 31 to August 2, in Long Beach, California. Attendees can explore Alcon’s latest surgical advancements through scientific presentations and hands-on dem
- Opus Genetics and the Global RDH12 Alliance Partner to Advance RDH12 Gene Therapy for Inherited Childhood Blindnesshttps://modernod.com/news/opus-genetics-and-the-global-rdh12-alliance-partner-to-advance-rdh12-gene-therapy-for-inherited-childhood-blindness/2482902/Opus Genetics announced a partnership with the Global RDH12 Alliance to advance Opus’ gene therapy program for patients with vision loss due to retinol dehydrogenase 12 (RDH12) gene mutations. The Alliance serves as a collaborative platform uniting advocacy groups dedicated to RDH
- Annexon Completes Enrollment in Phase 3 ARCHER II Trial of Vonaprument for GAhttps://modernod.com/news/annexon-completes-enrollment-in-phase-3-archer-ii-trial-of-vonaprument-for-ga/2482901/Annexon announced enrollment has been completed in the phase 3 ARCHER II trial of vonaprument (formerly ANX007) for dry age-related macular degeneration (AMD) with geographic atrophy (GA). The company remains on track to report topline data in the second half of 2026. Accordin
- EssilorLuxottica to Acquire Ophthalmic Lens Materials Division of PUcorehttps://modernod.com/news/essilorluxottica-to-acquire-ophthalmic-lens-materials-division-of-pucore/2482895/EssilorLuxottica has signed an agreement with the South Korean-based PUcore for the acquisition of all its assets and entities involved in the development, manufacturing and sale of monomers used in the production of high index ophthalmic lenses. The assets acquired by EssilorLuxottica inclu
- Topcon Partners with OKKO Health to Advance Home-Based Vision Monitoring and Patient Engagementhttps://modernod.com/news/topcon-partners-with-okko-health-to-advance-home-based-vision-monitoring-and-patient-engagement/2482894/Topcon Healthcare announced an investment in OKKO Health, a UK-based provider of vision testing software. While financial terms of the deal were not disclosed, the investment positions Topcon as the lead in OKKO Health’s seed funding round.
- Viatris Fails Phase 3 Study of MR-139 for Blepharitishttps://modernod.com/news/viatris-fails-phase-3-study-of-mr-139-for-blepharitis/2482893/Viatris announced that its phase 3 study evaluating the efficacy and safety of pimecrolimus 0.3% (MR-139) for blepharitis did not meet its primary endpoint of complete resolution of debris after six weeks of twice daily dosing. The MR-139 3001 phase 3 trial cons
- Harrow Enters into Commercialization Agreement with Samsung Bioepis for Biosimilars Portfolio in the UShttps://modernod.com/news/harrow-enters-into-commercialization-agreement-with-samsung-bioepis-for-ophthalmology-biosimilars-portfolio-in-the-us/2482890/Harrow announced that it has entered into a definitive agreement with Samsung Bioepis to secure the exclusive US commercial rights to the ophthalmology biosimilar portfolio of Samsung Bioepis, which includes Byooviz (ranibizumab-nuna), an FDA-ap
- Nicox and Kowa Sign Agreement for Exclusive Rights to Glaucoma Treatment NCX 470 in US and Unlicensed Territorieshttps://modernod.com/news/nicox-and-kowa-sign-agreement-for-exclusive-rights-to-glaucoma-treatment-ncx-470-in-us-and-all-unlicensed-territories/2482889/Kowa has gained exclusive rights to develop and commercialize NCX 470, Nicox’s nitric oxide (NO)-donating bimatoprost eye drop for the lowering of IOP in patients with glaucoma or ocular hypertension in the US and all other territories of the world excludin